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CASE LETTERSFig 1. Granulomatous dermatitis at varicella-zoster virus
vaccination site: violaceous plaque on the left upper
extremity.
Fig 2. Granulomatous dermatitis with histiocytes
(open arrow), multinucleated giant cells (closed arrow),
plasma cells (closed star), and eosinophils (open star).
(Hematoxylin-eosin stain; original magnification: 340.)Varicella-zoster virus vaccinationeinduced
granulomatous dermatitis
To the Editor:Herpes zoster is caused by reactivation
of latent varicella-zoster virus (VZV) and a live
attenuated VZV vaccine is recommended in adults
older than 50 years to reduce herpes zoster risk.
The vaccine is usually well tolerated and
adverse reactionsesuch as injection-site erythema,
tenderness, pruritus, and burningeare rare.
We report a 77-year-old woman who presented
with an intermittently tender, slightly indurated,
nonscaling, violaceous plaque on the upper aspect
of her left arm. This began after receiving a herpes
zoster vaccination at the site 9 months earlier (Fig 1).
Her medical history included breast cancer treated
by lumpectomy and radiation therapy, acoustic
neuroma, hearing loss, and hypertension.
A skin biopsy specimen from the plaque on
the upper aspect of her left arm was taken.
Histopathological examination showed an interstitial
dermal inflammatory infiltrate composed of lympho-
cytes, histiocytes, eosinophils, plasma cells, and
numerous giant cells (Fig 2). There was focal dermal
fibrosis and collections of perivascular plasma cells.
No evidence of foreign body was noted by polarized
light examination and viral cytopathic effect was
not identified. A VZV immunostain was negative
for VZV antigen expression. Acid-fast bacillus, Fite,
and periodic acideSchiff stains were negative for
infectious organisms.
The development of a local granulomatous
dermatitis confined to the site of vaccination is very
rare. Vaccines that have been noted in association
with the development of a granulomatous dermatitis
include: tetanus vaccine, hepatitis B, and BCG
vaccine.1-3 Whereas pseudolymphomatous reaction
has been recently reported as a result of herpes
zoster vaccination,4 the development of granuloma-
tous dermatitis such as we observed in our
patient has not yet been described to our knowledge.
In contrast, the development of a spectrum of
granulomatous reactions arising at the site of
previous herpes zoster lesions in immune competent
and immunocompromised patients has been well
appreciated.5
Given the location of the granuloma in our patient
at the site of VZV vaccination, it most likely repre-
sents an immune reaction induced by the vaccina-
tion, akin to the granulomatous reaction that may
occur at the site of previous herpes zoster lesions.J AM ACAD DERMATOL Open access under CC BY-NC-ND license.Cutaneous granulomas have been reported to
occur within weeks to years after herpes
zoster infection, with the average interval
between the acute infection and the appearance
of granulomas of 6 months. In our patient, the
granuloma appeared shortly after her VZV
vaccination, in a time frame similar to that of
postherpetic granulomas, further supporting the
hypothesis that the process is analogous to the
immunologic changes playing a role in the etiology
of postVZV granuloma.
To our knowledge, this is the first case of a
granulomatous dermatitis occurring at the site of
VZV vaccination. Whereas the development of
granulomatous reactions at the site of prior herpes
zoster lesions has been well appreciated, the
occurrence of such changes at the site of VZV
vaccination has not been reported to our knowledge.OCTOBER 2014 e131
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e132 LettersOur case raises the awareness and recognition of
granulomatous dermatitis as a new adverse cuta-
neous reaction to VZV vaccination.
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Spurious elevation of aspartate
aminotransferase in a patient on isotretinoin
To the Editor: Approximately 11% of patients on
isotretinoin develop a mild reversible transaminitis.1
We report a case of spurious elevation of aspartate
aminotransferase (AST) during treatment for acne.
A 15-year-old male with recalcitrant nodulocystic
acne was started on isotretinoin 20 mg daily. He had
a history of Hodgkin lymphoma that was in remis-
sion for 1 year. Initial screening laboratory investi-
gation results were normal except for an elevated
AST at 61 /L (range 15-45 /L). He denied alcohol
consumption. At his 1-month follow-up visit, the AST
level was 77 /L, while other liver enzymes remainednormal. Because we had observed this finding in
other patients at the satellite center where he was
seen, we considered whether the method of pro-
cessing the specimen might be a factor. The patient’s
blood had been drawn and centrifuged on-site,
within minutes of collection. The specimen was
packaged in a cooler and transported by courier
several miles to the central hospital laboratory for
testing. The AST value of 77 /L was obtained using a
plasma separator tube (PST), on a plasma specimen.
Using a serum separator tube (SST), a sample of
serum from the same blood draw revealed a normal
AST (29 /L). Enzyme levels remained within the
normal range for the duration of therapy while using
SSTs for testing.
Samples collected in both SSTs and PSTs are
centrifuged after collection, but while SSTs segregate
cells and platelets away from the serum, PSTs do not
isolate platelets well, leaving them in the plasma.2 If a
specimen is tested immediately after processing,
then either a PST or SST may be used. In our case,
prolonged plasma exposure to disintegrating plate-
lets in a transported PST tube was the likely cause of
the spuriously elevated AST results.2 Spurious AST
elevation can result from other collection errors,
such as improper tube selection with a light blue
anticoagulant tube, as well as from iatrogenic hemo-
lysis from using a too-small venipuncture needle.3
Elevations in serum alanine aminotransferase
(ALT) and AST result from tissue injury or increased
cell permeability, which release aminotransferases
into the circulation. ALT is a cytosolic enzyme found
predominantly in the liver, with much smaller quan-
tities in heart and skeletal muscle.4,5 AST is both a
cytosolic and a mitochondrial isoenzyme. High
concentrations ofASTare found in a variety of tissues,
including the liver, heart, skeletal muscle, and blood
components. AST elevation may result from amyriad
of causes, ranging from muscle injury to hemolysis.5
While an elevated AST level may reflect liver or
muscle injury andmerits careful evaluation, it is useful
to understand other causes of isolated AST elevation,
such as in this case, an artifact of sample collection.
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